Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 6/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | TYMS | P04818 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.32 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | G6PD | P11413 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | CCR6 | P51684 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1399319 | 0.82 | PTGS2 (0.46) | HTR2APTGS2PTGS1SLC6A4MAPT | |
| SCHEMBL1399263 | 0.79 | PTGS2 (0.45) | HTR2AHTR2CPTGS2PTGS1SLC6A4 | |
| SCHEMBL1399334 | 0.74 | KIF11 (0.43) | HTR2AHTR2CPTGS2PTGS1SLC6A4 | |
| SCHEMBL1399225 | 0.73 | IFNAR1 (0.44) | HTR2APTGS2PTGS1SLC6A4MAPT | |
| SCHEMBL1399394 | 0.73 | GPR84 (0.46) | HTR2ASLC6A4KCNH2SLC6A2 | |
| SCHEMBL1399244 | 0.72 | IDO1 (0.44) | HTR2APTGS2PTGS1SLC6A4KCNH2 | |
| SCHEMBL1399291 | 0.71 | GPR84 (0.47) | HTR2AHTR2CSLC6A4SLC6A2 | |
| SCHEMBL1399327 | 0.70 | SLC6A4 (0.42) | HTR2ASLC6A4KCNH2KDM4EALDH1A1 | |
| SCHEMBL1399435 | 0.70 | TUBB4A (0.43) | MAPTSMN1; SMN2KDM4EALDH1A1PKM | |
| SCHEMBL1399262 | 0.70 | IDO1 (0.39) | HTR2ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1860100-B1 | 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRI | LUNDBECK & CO AS H (DK) | 2011-03-02 | — | — | EP | claimed |
| US-7737170-B2 | Uses of 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRIS | H. LUNDBECK A/S (DK) | 2010-06-15 | — | — | US | claimed |
| US-7563908-B2 | 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRI | H. LUNDBECK A/S (DK) | 2009-07-21 | — | — | US | claimed |
| US-20080214645-A1 | USES OF 2-(1H-INDOLYLSULFANYL)-BENZYL AMINE DERIVATIVES AS SSRIS | H. LUNDBECK A/S (DK) | 2008-09-04 | — | — | US | claimed |
| EP-1860100-A2 | 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRI | H. Lundbeck A/S (DK) | 2007-11-28 | — | — | EP | claimed |
| US-20060160880-A1 | 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRI | H. LUNDBECK A/S (DK) | 2006-07-20 | — | — | US | claimed |
| EP-1860100-B1 | 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRI | LUNDBECK & CO AS H (DK) | 2011-03-02 | — | — | EP | disclosed |
| US-7737171-B2 | Uses of 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRIS | H. LUNDBECK A/S (DK) | 2010-06-15 | — | — | US | disclosed |
| US-7737170-B2 | Uses of 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRIS | H. LUNDBECK A/S (DK) | 2010-06-15 | — | — | US | disclosed |
| US-7652150-B2 | 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRIs | H. LUNDBECK A/S (DK) | 2010-01-26 | — | — | US | disclosed |
| US-7563908-B2 | 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRI | H. LUNDBECK A/S (DK) | 2009-07-21 | — | — | US | disclosed |
| US-20080214644-A1 | 2-(1H-INDOLYLSULFANYL)-BENZYL AMINE DERIVATIVES AS SSRI | H. LUNDBECK A/S (DK) | 2008-09-04 | — | — | US | disclosed |
| US-20080214645-A1 | USES OF 2-(1H-INDOLYLSULFANYL)-BENZYL AMINE DERIVATIVES AS SSRIS | H. LUNDBECK A/S (DK) | 2008-09-04 | — | — | US | disclosed |
| US-20080176922-A1 | USES OF 2-(1H-INDOLYLSULFANYL)-BENZYL AMINE DERIVATIVES AS SSRIS | H. LUNDBECK A/S (DK) | 2008-07-24 | — | — | US | disclosed |
| EP-1860100-A2 | 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRI | H. Lundbeck A/S (DK) | 2007-11-28 | — | — | EP | disclosed |
| EP-1701940-A1 | 2-(1H-INDOLYLSULFANYL)-BENZYL AMINE DERIVATIVES AS SSRI | H.Lundbeck A/S (DK) | 2006-09-20 | — | — | EP | disclosed |
| US-20060160880-A1 | 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRI | H. LUNDBECK A/S (DK) | 2006-07-20 | — | — | US | disclosed |
| WO-2005061455-A1 | 2-(1H-INDOLYLSULFANYL)-BENZYL AMINE DERIVATIVES AS SSRI | H. LUNDBECK A/S (DK) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160880-A1 | 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRI | TPH1, TPH2, HTR2B | HTR2A 8/4885HTR2C 4/4885PTGS2 1348/4885 |
| US-20080176922-A1 | USES OF 2-(1H-INDOLYLSULFANYL)-BENZYL AMINE DERIVATIVES AS SSRIS | TPH2, TPH1, HTR1B | HTR2A 8/4885HTR2C 5/4885PTGS2 1289/4885 |
| US-20080214645-A1 | USES OF 2-(1H-INDOLYLSULFANYL)-BENZYL AMINE DERIVATIVES AS SSRIS | TPH2, TPH1, HTR1B | HTR2A 8/4885HTR2C 5/4885PTGS2 1289/4885 |
| US-20080214644-A1 | 2-(1H-INDOLYLSULFANYL)-BENZYL AMINE DERIVATIVES AS SSRI | TPH2, TPH1, HTR2B | HTR2A 6/4885HTR2C 4/4885PTGS2 1282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.